Eric M. Ostertag
Net Worth
Last updated:
What is Eric M. Ostertag net worth?
The estimated net worth of Dr. Eric M. Ostertag is at least $20,156,331 as of 8 Aug 2022. He owns shares worth $8,002,381 as insider, has earned $8,719,230 from insider trading and has received compensation worth at least $3,434,720 in Poseida Therapeutics, Inc..
What is the salary of Eric M. Ostertag?
Dr. Eric M. Ostertag salary is $858,680 per year as Chief Executive Officer & Director in Poseida Therapeutics, Inc..
How old is Eric M. Ostertag?
Dr. Eric M. Ostertag is 52 years old, born in 1973.
What stocks does Eric M. Ostertag currently own?
As insider, Dr. Eric M. Ostertag owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Poseida Therapeutics, Inc. (PSTX) | Chief Executive Officer & Director | 838,824 | $9.54 | $8,002,381 |
What does Poseida Therapeutics, Inc. do?
Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company develops P-PSMA-101, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in Phase I trial for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC). It is also developing P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; and P-MUC1C-ALLO1 that is in Phase I trial for treating a range of solid tumors, including breast, ovarian, and other epithelial-derived cancers. In addition, the company engages in the development of P-CD19CD20-ALLO1 for B cell malignancies and other autoimmune diseases; and P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for multiple myeloma. Further, it is developing P-PSMA-ALLO1, an allogeneic CAR-T product candidate for treating mCRPC. Additionally, the company engages in the development of P-OTC-101 and P-FVIII-101 that are clinical stage liver-directed gene therapies; and other allogeneic dual CAR candidates. It has a research collaboration and license agreement with Takeda Pharmaceutical Company Limited. The company was incorporated in 2014 and is headquartered in San Diego, California.
Eric M. Ostertag insider trading
Poseida Therapeutics, Inc.
Dr. Eric M. Ostertag has made 32 insider trades between 2021-2022, according to the Form 4 filled with the SEC. Most recently he purchased 142,857 units of PSTX stock worth $500,000 on 8 Aug 2022.
The largest trade he's ever made was exercising 160,696 units of PSTX stock on 3 Aug 2022. As of 8 Aug 2022 he still owns at least 838,824 units of PSTX stock.
Poseida Therapeutics key executives
Poseida Therapeutics, Inc. executives and other stock owners filed with the SEC:
- Dr. Eric M. Ostertag (52) Chief Executive Officer & Director
- Mr. Harry J. Leonhardt (68) Gen. Counsel, Chief Compliance Officer & Corporation Sec.
- Mr. Mark J. Gergen (62) Pres, Chief Bus. Officer & Director